### FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF	<b>CHANGE</b>

# S IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Nash Duane				2. Issuer Name and Ticker or Trading Symbol Akebia Therapeutics, Inc. [ AKBA ]									ionship of Reportin all applicable) Director		100	6 Owner	
(Last) (First) (Middle) C/O AKEBIA THERAPEUTICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 10/03/2016								Offic belov	er (give title w)		er (specify bw)		
245 FIRST STREET					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBRIDGE MA	<b>A</b> 0	02142											X		n filed by Mor	e Reporting F re than One F	
(City) (Sta	ate) (2	Zip)															
	Tabl	le I - No	on-Deriva	ative	Secu	ıritie	s Ac	quire	d, Di	sposed o	f, or B	enefici	ally (	Owne	ed		
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/N				Execution Date,		3. Transaction Code (Instr. 8)  4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar				nd 5) Secu Bene Owne		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect			
								Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)			(1130.4)
Common Stock <sup>(1)</sup> 10/03/20				)16			S		1,981(2)	D	\$8.95	81 <sup>(3)</sup> 2		27,648	D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise (Instr. 3)  Price of Derivative Security  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)  3. A. Deemed Execution Date, if any (Month/Day/Year)		Code ( 8)	ansaction of ode (Instr. Derivative		ative rities ired esed 3, 4	6. Date Exercisable and Expiration Date Expiration  Date Expiration Exercisable Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. : and 4)  Amount or Number of		t		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)			

#### **Explanation of Responses:**

- 1. 47,525 shares of restricted stock (as adjusted from 27,157 shares prior to the 1.75-for-1 stock split effected on March 6, 2014) were awarded on December 23, 2013. Fifty percent of the shares vested on December 23, 2014. The remaining fifty percent vest ratably on the first day of each calendar quarter over three years from the first anniversary of the grant date until fully vested, assuming continued service through the applicable vesting date.
- 2. Shares sold by reporting person pursuant to a 10b5-1 plan to pay taxes in connection with the vesting of restricted stock pursuant to the December 23, 2013 award described in footnote 1.
- 3. The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$8.88 to \$9.00, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

## Remarks:

Nicole R. Hadas, Attorney-in-Fact for Duane Nash

10/04/2016

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.